News Ipsen

Stocks

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-10 EDT			5-day change	1st Jan Change
162.70 ^EUR	-3.61%		-4.69%	+36.72%

07-09	Wall Street Ignores the Sirens
07-09	Ipsen Reports Positive Topline Phase III Results for Dysport in Both Episodic and Chronic Migraine	CI

All News

Mentions Relevance

07-10	Ipsen - Dysport is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine	AQ
07-09	Ipsen Reports Positive Topline Phase III Results for Dysport in Both Episodic and Chronic Migraine	CI
07-09	Ipsen's Migraine Treatment Meets Primary Endpoints in Late-stage Trial	MT
07-09	Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.	GL
07-07	Ipsen - Half year statement - 2026 06 30	GL
07-07	AlphaValue/Baader Europe Cuts Ipsen Price Target Amid Future Patent Expiries, Mid-term Risks	MT
07-06	IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2026	GL
07-06	Ipsen: Reassessing mid-term risks
07-06	BlackRock tops 5% stake in Ipsen
07-03	IPSEN - Buy-back programme - Art 5 of MAR - Week 26- 2026	GL
07-01	AlphaValue/Baader Europe Downgrades Ipsen to Add, Lifts PT	MT
07-01	Oddo BHF still neutral on Ipsen after a new acquisition
07-01	Ipsen to Acquire Memo Therapeutics in Up to EUR700 Million Deal	MT
07-01	Ipsen lines up another bolt-on acquisition
07-01	French biotech Ipsen to buy Memo Therapeutics for $230 million upfront	RE
07-01	Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio	GL
06-30	Ipsen S.A. entered into a definitive share purchase agreement to acquire Memo Therapeutics AG for over ?700 million.	CI
06-30	Ipsen Extends Its Rally, Backed by Oddo BHF
06-29	Health Care Flat as Risk Appetite Rebounds - Health Care Roundup	DJ
06-29	RBC Capital weighs in on Ipsen acquisition
06-29	French biotech company Ipsen to buy Kartos Therapeutics for $450 million	RE
06-29	Ipsen strengthens its hematology franchise with the acquisition of Kartos Therapeutics
06-29	Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion	MT
06-29	Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline	GL
06-28	Ipsen S.A. entered into a definitive merger agreement to acquire Kartos Therapeutics, Inc. for $1.8 billion.	CI